Study: U.S. Needs Better Drug Safety Tracking
A new study suggests that the U.S. Food and Drug Administration (FDA) should continually review drugs for as long as they are on the market to identify any new problems with safety. The Institute of Medicine says that the FDA should craft a document that is available to the public and outlines the risks that emerge throughout the “lifecycle” of a drug. The FDA has been criticized for slowly responding to dangerous side effects that become clearer once the medication hits the market. Such was the case with Vioxx